Navigation Links
Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival

sis pathway, including paclitaxel. In September 2006, Synta reported positive Phase 2b results for STA-4783 in combination with paclitaxel in a double-blind, randomized, multi-center clinical trial in patients with stage IV metastatic melanoma. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma. Synta plans to initiate a pivotal Phase 3 clinical trial for STA-4783 in metastatic melanoma in mid-2007.

Based on the broad-acting potential of its novel mechanism of action, and the activity seen in laboratory experiments in other cancer types, Synta plans to investigate the use of STA-4783 in additional cancers and in combination with other agents, including initiating one or more Phase 2 studies in other cancer indications later in the year.

About Metastatic Melanoma

Melanoma, the most deadly form of skin cancer, arises from melanocytes, the pigment-producing cells of the skin. According to the American Cancer Society, melanoma accounts for approximately five percent of all skin cancers but causes about 75% of all skin cancer-related deaths. An estimated 60,000 people will be diagnosed and nearly 8,200 people will die from melanoma this year in the U.S. alone. If diagnosed and surgically removed while localized in the outermost skin layer, melanoma is potentially curable; however, for patients with metastatic disease, the prognosis is poor, with limited available treatments and an expected survival of only six to nine months. The incidence of melanoma has increased more rapidly than any other cancer during the past ten years. The FDA has not approved a novel, small molecule drug for the treatment of metastatic melanoma in over 30 years.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical cond
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Synta Pharmaceuticals to Host Conference Call Today
2. Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... June 19, 2013 , ... disease (PD) patients as add-on to levodopa ... in motor symptoms in fluctuating PD patients as ... Newron Pharmaceuticals S.p.A. ("Newron"), a research and development ... and its partner Zambon S.p.A., a pharmaceutical company ...
(Date:6/18/2013)... , June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... focused on the development and commercialization of novel bile ... the pricing of an underwritten public offering of 1,730,000 ... price of $33.01 per share.  In addition, Intercept has ... to an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... Havel,s Incorporated, the Cincinnati-based market leader in ... new echogenic ultrasound needle which could help reduce ... new echogenic needles using their new, innovative Micro ... surfaces to reflect sound waves back to the ...
... Inc., a global leader in temperature-controlled biomaterial storage, ... biotechnology and pharmaceutical industries, has announced the appointment ... chain. Based at the company,s U.S. ... activities for its sample relocation services, global logistics ...
Cached Medicine Technology:Havel's Incorporated Helping to Reduce Radiation Exposure with New EchoTuohy™ Ultrasound Needle 2BioStorage Technologies Appoints New Global Director of Supply Chain 2
(Date:6/19/2013)... Everyone is looking for ways to improve general health. Sublime Beauty® ... is called Skin Brushing . Skin Brushing can be incorporated ... to improve health and skin quality. It is fun to ... Brushing improves general health because:, , it boosts ... drain toxins , it clears skins of dead cells ...
(Date:6/19/2013)... 19, 2013 Brand new Hypertrophy Max bonus just ... day sale on the Hypertrophy Max program. Vince and Ben ... so those that are interested must act quickly. , What is ... Max bonus is a free 12 month all access pass to ... to Ryan Davids "Live Large TV is a Monday night show ...
(Date:6/19/2013)... 19, 2013 The Zac Brown Band ... country and folk music genre. This band hails from Atlanta, ... lead vocals and guitarist), Jimmy De Martini (working with fiddle ... and in vocals), Coy Bowles (guitarist and keyboardist), Chris Fryar ... The band was formed in 2002, but they gained ...
(Date:6/19/2013)... A man returning from war is not likely to ... his debut book titled RED DANCER JOURNEY, author Rafael Fraguada pens ... home, looking for the right place and people to mend his ... from the Vietnam War, returns to New York City, he meets ... Wings, a wealthy acquaintance from a tiny Midwest college they both ...
(Date:6/19/2013)... Asheville, NC (PRWEB) June 19, 2013 ... Depot has partnered with Brookstone Lodge on some summertime ... vacation or locals are looking for a fun staycation, ... great fun for couples and families. Asheville is so ... to enjoy, so having several options that guests can ...
Breaking Medicine News(10 mins):Health News:A Fast and Fun Way to Better Skin Quality and Overall Health, says Sublime Beauty® 2Health News:New Hypertrophy Max Bonus Just Released and Only Available for 24 Hours 2Health News:Zac Brown Band Tickets for Raleigh, Columbia, Darien Center, Gilford, Minneapolis, Holmdel, Pittsburgh, Camden, Atlanta, Boston, Bethel, Toronto & Hartford Now Available 2Health News:Rafael Fragauda’s New Book Underlines Post Traumatic Stress Disorder 2Health News:Fun Depot Partners with Brookstone Lodge on Summer Packages 2
... News) -- Scientists have identified common genetic variations that may ... Vitamin E is an antioxidant found in a number of ... as peppers, tomatoes and pumpkins. Previous research has found that ... the vitamin in a person,s body. It,s been suspected that ...
... October, 2010 Elsevier / MC Strategies, a pioneer ... organizations, has partnered with the Association of periOperative Registered ... Nursing Skills: Perioperative Collection, the only perioperative-specific set of ... with the Standards and Recommended Practices. ...
... (SFMU) has chosen Springer to publish its scientific research ... mdecine d,urgence . Bruno Riou, Professor on the Pierre ... Universities is editor-in-chief of this official society journal. ... d,urgence is targeted at the community of French ...
... , WEDNESDAY, Oct. 20 (HealthDay News) -- In ... your adaptability and resilience, a new study suggests. Researchers ... national survey each year from 2001 to 2004. Those who ... than those exposed to high levels of adversity or no ...
... GOLDEN, Colo. (October 20, 2010) A new independent study ... patients at 5-star rated hospitals had a 72% lower risk ... an enormous gap that has held steady over the past ... the study, if all hospitals performed at the level of ...
... , TUESDAY, Oct. 19 (HealthDay News) -- Men with ... death from heart disease and all causes, a finding that ... for cardiovascular disease, according to new research. The study ... for about seven years. At the start of the study, ...
Cached Medicine News:Health News:Elsevier/MC Strategies and AORN launch perioperative nursing skills collection 2Health News:New ratings of American hospitals released with quality study by HealthGrades 2Health News:New ratings of American hospitals released with quality study by HealthGrades 3Health News:Low Testosterone May Raise Risk of Early Death: Study 2
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 4.0mm....
Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
Medicine Products: